Study Subject Participation Status eligible | Informed Consent
Item
patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.
boolean
C2348568 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
Outpatients | Age
Item
male or female outpatients, 18 years of age and older.
boolean
C0029921 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Hypertensive disease Stage | Sitting systolic blood pressure mean
Item
patients with stage 2 hypertension. patients must have a mssbp ≥ 160 mmhg and < 200 mmhg at study visit 5 (randomization).
boolean
C0020538 (UMLS CUI [1,1])
C0699749 (UMLS CUI [1,2])
C1319893 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
Body mass index
Item
patients must have a bmi ≥ 30 kg/m2 but ≤ 45 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Blood pressure determination | Sitting diastolic blood pressure mean | Sitting systolic blood pressure mean
Item
office blood pressure measured by cuff (msdbp ≥ 110 mmhg and/or mssbp ≥ 200 mmhg) at any visit.
boolean
C0005824 (UMLS CUI [1])
C1319894 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
C1319893 (UMLS CUI [3,1])
C0444504 (UMLS CUI [3,2])
Investigational New Drugs
Item
use of other investigational drugs within 30 days of enrollment, or 5 half-lives, which ever is longer.
boolean
C0013230 (UMLS CUI [1])
Aliskiren | Hydrochlorothiazide | Combined Modality Therapy Dose Stable | Study Subject Participation Status
Item
use of aliskiren and/or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren and/or aliskiren hctz as treatment within 30 days of visit 1.
boolean
C1120110 (UMLS CUI [1])
C0020261 (UMLS CUI [2])
C0009429 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
C2348568 (UMLS CUI [4])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Therapeutic class Same | Angiotensin-Converting Enzyme Inhibitors | Renin inhibitor
Item
history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (ace inhibitors or renin inhibitors) as the study drugs.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C3858838 (UMLS CUI [2,3])
C0445247 (UMLS CUI [2,4])
C0003015 (UMLS CUI [3])
C1960108 (UMLS CUI [4])
Secondary hypertension
Item
history or evidence of a secondary form of hypertension.
boolean
C0155616 (UMLS CUI [1])
Refractory hypertension | Pharmacotherapy Triple Unresponsive to Treatment | Pharmaceutical Preparations Maximum Tolerated Dose | Diuretics | Blood Pressure Goal failed | Combined Modality Therapy | Pharmaceutical Preparations Quantity Dose Stable
Item
refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmhg). therapy with a fixed dose combination of two active substances represent two drugs.
boolean
C0860493 (UMLS CUI [1])
C0013216 (UMLS CUI [2,1])
C0205174 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C0752079 (UMLS CUI [3,2])
C0012798 (UMLS CUI [4])
C0005823 (UMLS CUI [5,1])
C0679840 (UMLS CUI [5,2])
C0231175 (UMLS CUI [5,3])
C0009429 (UMLS CUI [6])
C0013227 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
C0178602 (UMLS CUI [7,3])
C0205360 (UMLS CUI [7,4])
Antihypertensive Agents Quantity
Item
patients on 4 or more antihypertensive medications.
boolean
C0003364 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Long QT Syndrome | QTc Duration | Gender
Item
long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening.
boolean
C0023976 (UMLS CUI [1])
C0860814 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0079399 (UMLS CUI [3])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])